Clinical trial · Interventional
Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
Phase I Clinical Trial Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No subjects were enrolled in this study, the PI will seek funding and revise the protocol for resubmisson at a later date
Summary
Brief summary (as posted)
A proof of concept clinical trial to assess the synergism of curcumin (CURC) and ursolic acid (UA). Before further testing within formal cancer clinical trials, we must (1) evaluate the bioavailability and safety, (2) confirm the presence of metabolites in the target organ, and (3) validate the appropriate mechanism of effect
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcumin | Drug | — | UNRESOLVED |
| Ursolic Acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Ursolic Acid
- description
- Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
- interventionNames
- Drug: Ursolic Acid
- type
- EXPERIMENTAL
- label
- Curcumin
- description
- Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
- interventionNames
- Drug: Curcumin
- type
- EXPERIMENTAL
- label
- Ursolic Acid and Curcumin
- description
- Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have proven diagnosis of prostate cancer with Gleason Group 3 or lower and planning to undergo radical prostatectomy * Be able to give informed consent * Be age 18 or older * Able to stop supplements Exclusion Criteria: * Unable to give informed consent * Age \< 18 * High-risk prostate cancer or suspected metastasis * Unable to swallow pills * Unable to stop supplements
References
Publications (0)
Data not yet available